Stock PRME PRIME MEDICINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Prime Medicine, Inc.

Equities

PRME

US74168J1016

Real-time Estimate Cboe BZX
Other stock markets
 03:43:25 2024-05-10 pm EDT 		5-day change 1st Jan Change
5.695 USD -0.44% Intraday chart for Prime Medicine, Inc. +2.24% -35.50%
02:15pm Earnings Flash (PRME) PRIME MEDICINE Reports Q1 Revenue $591,000 MT
Apr. 29 Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (PRME) PRIME MEDICINE Reports Q1 Revenue $591,000
MT
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
GL
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
GL
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
AQ
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
GL
Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance
MT
Prime Medicine Gets FDA Clearance for PM359 IND Application
DJ
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
GL
Prime Medicine Announces FDA Clearance of Investigational New Drug Application for PM359 for the Treatment of Chronic Granulomatous Disease
CI
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
GL
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
AQ
Chardan Initiates Prime Medicine With Buy Rating, Price Target is $17
MT
Chardan Initiates Prime Medicine at Buy With $17 Price Target
MT
Wedbush Initiates Prime Medicine With Outperform Rating, $12 PT; Notes Positive Long-Term Outlook on Gene Editing Platform
MT
Guggenheim Cuts Prime Medicine's Price Target to $20 From $24, Maintains Buy Rating
MT
Prime medicine reports full year 2023 financial results and provides business updates
AQ
Prime Medicine 2023 Net Loss Narrows
MT
Prime Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
GL
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRME Stock
  4. News Prime Medicine, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW